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Abstract
Background: Restoring normal physical functioning is a major therapeutic aim in the management of rheumatoid
arthritis (RA). It is unknown, whether the extent of synovial inflammation quantified by musculoskeletal ultrasound
(US) can predict current or future capacity for physical functioning. To answer this question we investigated the
longitudinal relationship between physical function assessed by the health assessment questionnaire (HAQ) and
the German 7-joint ultrasound score (US7S) in a prospective cohort of patients with RA.
Methods: Patients with RA (n = 185 (46 with incident and 139 with prevalent disease) were followed for 30.9 ± 9.
1 months. Baseline and annual assessments comprised the disease activity score in 28 joints (DAS28), HAQ and
US7S. The US7S includes semiquantitative measurements of synovitis assessed by greyscale (GS) and power Doppler
(PD) in seven joints of the clinically dominant hand and foot, which are then aggregated in PD and GS synovitis
sum-scores (PDsynSS and GSsynSS). A linear mixed-effect model was used to assess the longitudinal relationship
between GSsynSS, PDsynSS and HAQ. We used standard and time-lag models to explore the association between
HAQ, and GSsynSS, PDsynSS and DAS28 measured at the same time or at the previous visit 12 months ago,
respectively.
Results: When the standard model was applied, in univariate analyses HAQ score was positively associated with
GSsynSS and PDsynSS with β coefficients significantly higher in incident than in prevalent disease. In multivariate
analysis both synSSs were individually no longer significant predictors of HAQ score. When using the time-lag
model, after adjustment for the previous DAS28 or HAQ score, both PDsynSS and GSsynSS were significantly and
negatively associated with the current HAQ.
Conclusions: US7 PD and GS synovitis sum-scores alone were positively associated with current functional status
reflected by the HAQ in patients with RA, and this relationship was stronger in patients with early disease. When
combined with the DAS28 or HAQ, US7 PD and GS synovitis sum-scores were predictive of the change in HAQ
score over one year.
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Background
Rheumatoid arthritis (RA) may lead to substantial func-
tional impairment caused by the combined effect of
potentially reversible inflammatory activity and irrevers-
ible destructive articular and periarticular damage [1–4].
The main objective of RA management is to prevent
and/or reverse the decline of physical functioning by
aggressive control of disease activity and thus halting the
structural progression.
The currently recommended tight control and treat-
to-target RA management strategies are guided by close
monitoring of disease activity using composite indexes
such as the disease activity score in 28 joints (DAS28),
simplified disease activity index (SDAI) or clinical dis-
ease activity score (CDAI) [5]. However, clinical disease
activity indexes also have several limitations [6]: clinical
examination may be poorly reproducible [7, 8] and may
fail to capture subclinical synovitis associated with
progressive joint damage [9, 10]), especially in the feet
[11–13]. Disease activity scores may be falsely increased
in some patients without evidence of synovitis due to
fibromyalgia [14].
An important question is whether these limitations of
conventional disease activity scores may be alleviated by
complementing clinical examination with musculoskel-
etal ultrasound (US), which has been shown to be more
sensitive [15–18] and reliable [19–21] in detecting syno-
vitis compared to physical examination. The German
US7 score (US7S) has been shown to be a feasible, reli-
able and sensitive tool for the US examination of inflam-
matory joint activity in RA [22–24]. The US7S includes
seven joints of the clinically dominant hand and foot,
consists of five additive sum-scores for synovitis (syn)
and tenosynovitis (ten) assessed by greyscale (GS) and
power-Doppler (PD), and an erosions score (ES). It is
unknown whether an US joint inflammation score may
contribute additional prognostic information on mea-
sures of functional impairment beyond the standard
clinical indexes.
In our longitudinal prospective cohort study, we have
systematically performed repeated clinical and US assess-
ments of joint inflammation (using the DAS28 and US7S)
and physical function evaluations (using the health assess-
ment questionnaire (HAQ)) in patients with early RA and
established RA. The main objectives of the present ana-
lysis were to examine the ability of US7S synovitis sum
scores (PDsynSS, GSsynSS) to predict the HAQ score
measured concurrently or 12 months later, either alone or
as an adjunct to the DAS28 (or previous HAQ).
Methods
Patients
Patients with early RA (n = 46) newly started on therapy
with conventional synthetic disease-modifying drugs
(csDMARDs) or glucocorticoids (incident cohort), and
139 patients with established RA (prevalent cohort) were
asked to participate in this this study. Diagnosis of RA
was based on the American College of Rheumatology/
European League against Rheumatism (EULAR) 2010
classification criteria for RA [25]. The patient character-
istics are provided in Table 1. All patients were recruited
from the outpatient rheumatology clinic at the Insti-
tute of Rheumatology in Prague and were followed
longitudinally according to a predefined protocol. In-
formed consent was obtained from all patients before
entry into the study. Patients on biological DMARDs
were not included in the study, because they are
followed separately in the Czech biologics ATTRA
registry. During the observation period, patients were
routinely treated by their rheumatologist. The study
was approved by the Ethics Committee of the Insti-
tute of Rheumatology in Prague (Reference number
3560/2010) and was conducted according to the
guidelines of the Declaration of Helsinki.
Outcome measurements
The same measures of clinical assessment and US im-
aging were applied at baseline and every 6 months dur-
ing the follow-up period. Physical function was assessed
by the HAQ [26] at baseline and then annually. For the
purpose of this analysis only clinical and US data col-
lected concurrently with the HAQ every 12 months were
used. Demographic and anthropometric data collection,
and data on rheumatoid factor (RF), and anti-
citrullinated protein antibody (ACPA) testing were per-
formed at baseline. Tender and swollen joint counts
were carried out on 28 joints by an experienced nurse,
in accordance with the EULAR recommendations [27].
C-reactive protein (CRP) was measured in a local labora-
tory using turbidimetry (Beckman Coulter, CA, USA).
For the purpose of this analysis, we have used the
DAS28 with CRP (DAS28-CRP) as the main outcome
measure of clinical activity.
Ultrasound imaging
The US examinations were performed by eight clinicians
who have undergone intermediate to advanced US train-
ing. The results of a practical exercise published else-
where [28] showed moderate interobserver agreement
for assessment of PD synovitis, substantial agreement for
assessment of GS synovitis, and excellent intrareader
agreement. We used the Esaote Mylab 60 equipment
(Esaote S.p.A., Genova, Italy) and a linear transducer
with an 18-MHz frequency. The power Doppler sensitiv-
ity was pre-set (pulse repetition frequency 750 Hz, wall
filter 3/5, persistence 4/16, colour flow mapping fre-
quency 7.1 MHz), and no adjustments of the Doppler
parameters were allowed.
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The patients were examined according to the
German US7 score in the following seven joint areas:
wrist, second and third metacarpophalangeal (MCP)
and second and third proximal interphalangeal (PIP)
and second and fifth metatarsophalangeal (MTP)
joints of the hand and foot that clinically was more
affected [22]. We used a modification of the original
German US7 [29], which is currently used and
endorsed by the authors of both the original and
modified versions (personal communication with M.
Backhaus). In contrast to the original US7, which ex-
amines synovitis of the MCP and PIP joints in GS
only from the palmar view; we assessed synovitis in
GS in this area using both the palmar and the dorsal
view. Further, while the original German US7 assesses
tenosynovitis/paratenonitis on the second and third
finger both from the palmar and dorsal aspect, we
assessed tenosynovitis only from the palmar aspect. Syno-
vitis in the GS was scored semiquantitatively (0 = absence,
1 =mild, 2 =moderate, 3 = severe synovitis), as follows:
grade 1 = a small hypoechoic/anechoic line beneath the
joint capsule; grade 2 = the joint capsule elevated parallel
to the joint area; and grade 3 = strong distension of the
joint capsule [30].
Synovitis and tenosynovitis were classified semiquanti-
tatively by PD, as follows: grade 0 = no intraarticular
color signal; grade 1 = up to three single colour signals
or two single signals and one confluent signal in the
intraarticular area; grade 2 = greater than grade 1 to
<50% of the intraarticular area filled with colour signals;
and grade 3 = ≥50% of the intraarticular area filled with
colour signals. Tenosynovitis in the GS was registered as
absent (0) or present (1). An overall GS and PD signal
score was calculated as the sum of GS synovitis, PD
synovitis and GS tenosynovitis and PD tenosynovitis
with the range of scores of 0–39 for GS synovitis, 0–39
for PD synovitis, 0–5 for GS tenosynovitis and 0–15 for
PD tenosynovitis. The ultrasonographers were unaware
of each patient’s clinical examination and laboratory
findings.
Statistical analysis
Differences in baseline variables between the included
patients with early (n = 46) and established (n = 139) RA
(incident and prevalent cohorts, respectively) were ex-
amined by the Mann-Whitney test (continuous vari-
ables) or Fisher’s exact test (categorical variables). A
linear mixed effects model (LMM) was used to study the
longitudinal relationship between the clinical measures
of disease activity (DAS28-CRP), US inflammatory score
(German US7 scores sum-scores for GS and PD syno-
vitis, GS and PD tenosynovitis, and erosions) as explana-
tory variables, and physical function (HAQ score) as a
dependent variable. Age, sex, rheumatoid factor (RF)
and anti-CCP status, body mass index (BMI) and disease
duration were also introduced in one of the multivariate
models as covariates. All the subsequently described
analytical models used in our study were pre-planned.
Table 1 Baseline characteristics
Total (N = 185) Incident RA (N = 46) Prevalent RA (N = 139) P value
Female (%) 76.8 69.6 79.1 0.066
Age (years) 55.2 (14.0) 51.7 (12.6) 56.4 (14.2) <0.001*
Disease duration (years) 6.3 (7.7) 0.8 (0.7) 8.1 (8.1) <0.001*
Symptom duration (years) 7.3 (7.7) 1.5 (1.8) 9.2 (8.0) <0.001*
BMI 26.7 (4.5) 27.5 (5.2) 26.4 (4.3) 0.020*
RF+ (%) 47.2 43.5 48.5 0.466
ACPA+ (%) 62.9 58.7 64.3 0.952
CRP (mg/l) 7.6 (9.0) 10.5 (12.6) 6.6 (7.1) 0.354
DAS28-CRP 3.7 (1.5) 4.0 (1.5) 3.6 (1.5) 0.192
GSsynSS 6.91 (6.39) 7.70 (5.62) 6.65 (6.61) 0.255
PDsynSS 4.02 (5.20) 5.24 (5.95) 3.61 (4.87) 0.438
GStenSS 0.66 (1.15) 0.78 (1.18) 0.63 (1.14) 0.842
PDtenSS 0.68 (1.63) 0.80 (1.75) 0.63 (1.59) 0.402
Erosions score 1.18 (2.10) 0.46 (1.50) 1.42 (2.21) <0.001*
HAQ 0.77 (0.73) 0.88 (0.73) 0.74 (0.73) 0.896
Oral glucocorticoids (%) 43.8 41.3 44.6 0.607
csDMARDs (%) 87.0 69.6 92.8 <0.001*
Values are mean (SD) if not stated otherwise. RA rheumatoid arthritis, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, CRP
C-reactive protein, DAS28 disease activity score in 28 joints, GS greyscale, PD power Doppler, syn synovitis, ten tenosynovitis, ES erosions score, SS sum-score, HAQ
health assessment questionnaire, csDMARDS conventional synthetic disease-modifying anti-rheumatic drugs. *Significant at p < 0.05
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To explore the influence of current disease activity
(assessed either clinically or by US) on the current HAQ
score, we used the standard (“current”) model. To ex-
plore the impact of previous disease activity (assessed ei-
ther clinically or by US) on the current HAQ score we
used a “time-lag” model. In the time-lag model the co-
variates measured at the previous visit (12 months be-
fore) are related to the outcome variable assessed at the
current visit. Also, the previous HAQ (assessed at the
previous visit 12 months earlier) was added to the model
(i.e. the first-order autoregression) to model change in
the HAQ score rather than absolute HAQ scores. The
proportion of variability in the HAQ scores explained by
given covariates or models was assessed using R2 and
compared to each other using analysis of variance
(ANOVA).
Participants with missing data on baseline characteris-
tics and parameters of disease activity were included in
the analysis by using multiple imputations using the
Markov chain Monte Carlo method with 30 imputations
obtained after 20 iterations. Variables included in imput-
ation models were all baseline covariates and parameters
of disease activity (variables with missing data were im-
puted and used as predictors, and variables with
complete data were used as predictors only). IBM SPSS
Statistics version 22 (SPSS Inc., Chicago, IL, USA) was
used for the analyses. All P values equal to or less than
0.05 were considered statistically significant.
Results
Descriptive analyses
The baseline characteristics of the whole cohort, and the
incident and prevalent cohorts, are shown in Table 1.
Most of the patients were female (77%), mean age was
55 years, 47% were RF-positive and 63% ACPA-positive.
At the baseline examination, 87% of the patients were
taking conventional csDMARDs, and 44% oral glucocor-
ticoids. The patients with early RA were younger (52 vs.
56 years; P < 0.001), had significantly shorter disease dur-
ation than patients with established disease (0.9 vs.
8.1 years; P < 0.001), had significantly lower erosions
scores (0.5 vs. 1.4; P < 0.001), and were less frequently
taking csDMARDs (69 vs. 93%; P < 0.001). Mean (SD)
length of follow up was 30.9 (9.1) months.
In the whole cohort, the average HAQ scores were
relatively stable over the 3-year follow-up period, while
both clinical and US parameters of disease activity im-
proved (Additional file 1). However, the evolution of
functional and activity measures in time was somewhat
different in the incident vs. prevalent cohorts (Additional
files 2 and 3). While the mean HAQ scores had dropped
during the first year of observation in patients with early
RA, there was a steady increasing trend in HAQ scores
in patients with established disease. Also, there was a
more pronounced decrease in both clinical and US activ-
ity parameters in the incident cohort than in the preva-
lent cohort since the baseline visit.
Cross-sectional associations between ultrasound
inflammatory score and physical function (standard or
current model)
In univariate analyses (Table 2) the HAQ score was posi-
tively associated with GSsyn, PDsyn, PDten and GSten
US7 sum-scores with β coefficients significantly higher
in patients with incident than in patients with prevalent
disease, respectively. However, the proportion of vari-
ability of the HAQ score explained by GSsynSS,
PDsynSS, GStenSS and PDtenSS was relatively small (R2
of 2–4% for US7S as compared to R2 of 41% for DAS28-
CRP), and the erosions score was not correlated with
HAQ score at all. In a multivariate analysis that included
conventional demographic, immunological and clinical
variables (Table 3), female gender, age and DAS28-CRP
were all significantly and positively associated with HAQ
score, while US7 sum-scores were individually no longer
significant predictors of HAQ score and the R2 of the
whole model improved only marginally after the addition
of US7 items (from 44.7 to 45.9; P < 0.001 for improve-
ment in R2).
Longitudinal associations between ultrasound
inflammatory score and physical function (time-lag
model)
When applying a time-lag model, in univariate analyses
only previous HAQ score and DAS28-CRP, but not the
US7 sum-score, was predictive of current HAQ score
measured 12 months apart (Table 4). However, in multi-
variate analyses (Table 5) after adjustment for previous
DAS28 and/or previous HAQ score, both previous
PDsynSS and GSsynSS were significantly and inversely
associated with the current HAQ score. Previous
PDsynSS remained a statistically significant predictor of
current HAQ score, even in a more extensive multivari-
ate model after adjustment for the most important con-
ventional demographic, immunological and clinical
variables (Table 6), and the percent variability of HAQ
score explained by this model was substantially im-
proved by the addition of the US7S sum-scores (from 32
to 39%, P < 0.001).
Additional analyses
One possible explanation for why previous higher values
of PDsynSS are associated (in the multivariate model)
with improvement of functional status between the pre-
vious and current visit, may be the fact that treatment of
RA was escalated between the previous and current visit.
To examine this we conducted several analyses with
PDsynSS (and DAS28, or HAQ) as exploratory variables
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and escalation of therapy (defined as new/increased use
of glucocorticoids or DMARDS within 6 months after
the index visit) as a dependent variable (see Additional
files 4 and 5). Although in univariate analyses
(Additional file 4) all parameters (PDsynSS, DAS28, and
HAQ) were positively associated with escalation of ther-
apy within the next 6 months, after adjustment for pre-
vious HAQ score or DAS28, previous PDsynSS was no
longer an independent predictor of escalation of therapy
(Additional file 5).
Table 3 Standard (current) model: multivariate analyses
Predictor Model without US-7 Model with US-7
β (95% CI) P value β (95% CI) P value
Female 0.211 (0.045; 0.376) 0.013 0.208 (0.044; 0.372) 0.013
Age (years) 0.149 (0.097; 0.201) <0.001 0.147 (0.096; 0.199) <0.001
BMI 0.008 (-0.007; 0.024) 0.276 0.008 (-0.007; 0.023) 0.291
RF+ or ACPA+ 0.029 (-0.115; 0.172) 0.696 0.029 (-0.114; 0.172) 0.691
Prevalent vs. incident RA -0.048 (-0.209; 0.113) 0.558 -0.050 (-0.212; 0.111) 0.541
DAS28-CRP 0.184 (0.155; 0.213) <0.001 0.202 (0.166; 0.238) <0.001
GSsynSS - -0.003 (-0.014; 0.008) 0.595
PDsynSS - -0.001 (-0.015; 0.014) 0.916
GStenSS - -0.062 (-0.129; 0.006) 0.073
PDtenSS - 0.018 (-0.032; 0.068) 0.487
Erosions score - 0.005 (-0.022; 0.032) 0.720
R2 (% variability explained) 44.7 45.9
Improved R2 - 1.1 <0.001*
Predicted variable is current health assessment questionnaire (HAQ) score. Comparison of models based on demographic, clinical and immunological parameters
with or without the German 7-joint ultrasound score (US7) sum-scores (SS). *P value of significance for improvement of prediction. BMI body mass index, RF
rheumatoid factor, ACPA anti-citrullinated peptide antibodies, GS greyscale, PD power Doppler, syn synovitis, ten tenosynovitis, ES erosions score. P-values
higlighted in italics are significant at p < 0.05
Table 2 Standard (current) model
Predictor RA β (95% CI) P value* P value** Percent variability explained - R2
DAS28-CRP all 0.186 (0.157; 0.216) <0.001 41.3
i 0.234 (0.174; 0.295) <0.001 0.072
p 0.171 (0.137; 0.204) <0.001
GSsynSS all 0.018 (0.011; 0.026) <0.001 3.2
i 0.035 (0.020; 0.050) <0.001 0.013
p 0.013 (0.004; 0.022) 0.003
PDsynSS all 0.025 (0.015; 0.035) <0.001 3.6
i 0.038 (0.021; 0.055) <0.001 0.056
p 0.018 (0.006; 0.030) 0.004
GStenSS all 0.048 (0.004; 0.092) 0.033 2.4
i 0.123 (0.039; 0.207) 0.004 0.038
p 0.019 (-0.032; 0.071) 0.460
PDtenSS all 0.051 (0.019; 0.082) 0.002 2.8
i 0.100 (0.039; 0.162) 0.001 0.064
p 0.033 (-0.003; 0.070) 0.073
ES all 0.007 (-0.022; 0.036) 0.632 0.3
i -0.024 (-0.102; 0.054) 0.549 0.390
p 0.013 (-0.019; 0.045) 0.416
Univariate analyses and interaction with incident (i) or prevalent (p) rheumatoid arthritis (RA). Predicted variable is current health assessment questionnaire (HAQ)
score, univariate predictors are current disease activity score in 28 joints using C-reactive protein (DAS28-CRP), sum-scores (SS) for greyscale (GS) and power
Doppler (PD) synovitis, GS and PD tenosynovitis (ten), and erosions score (ES). *P value of significance of given β. **P value of significance of difference between
incident and prevalent RA. P-values higlighted in italics are significant at p < 0.05
Závada et al. Arthritis Research & Therapy  (2017) 19:5 Page 5 of 10
Table 4 Time-lag model
Predictor RA β (95% CI) P value* P value** Percent variability explained - R2
Previous DAS28-CRP all 0.102 (0.062; 0.143) <0.001 29.0
i 0.072 (-0.008; 0.152) 0.079 0.353
p 0.115 (0.069; 0.161) <0.001
Previous GSsynSS all 0.003 (-0.006; 0.012) 0.530 7.4
i 0.000 (-0.019; 0.019) 1.000 0.713
p 0.004 (-0.007; 0.015) 0.465
Previous PDsynSS all -0.003 (-0.015; 0.009) 0.605 0.4
i -0.001 (-0.021; 0.019) 0.924 0.816
p -0.004 (-0.018; 0.011) 0.595
Previous GStenSS all 0.006 (-0.044; 0.056) 0.822 0.7
i 0.005 (-0.089; 0.099) 0.922 0.972
p 0.007 (-0.053; 0.066) 0.825
Previous PDtenSS all -0.005 (-0.041; 0.032) 0.801 0.5
i -0.019 (-0.092; 0.054) 0.606 0.655
p 0.000 (-0.042; 0.042) 1.000
Previous ES all 0.028 (-0.007; 0.062) 0.118 0.4
i -0.043 (-0.158; 0.072) 0.462 0.216
p 0.033 (-0.004; 0.070) 0.081
Previous HAQ all 0.740 (0.676; 0.803) <0.001 63.5
i 0.627 (0.496; 0.759) <0.001 0.050
p 0.775 (0.705; 0.846) <0.001
Univariate analyses and interaction with incident (i) or prevalent (p) rheumatoid arthritis (RA). Predicted variable is current HAQ score, univariate predictors are
previous disease activity score in 28 joints using C-reactive protein (DAS28-CRP), sum-scores for greyscale (GS) and power Doppler (PD) synovitis (syn), GS and PD
tenosynovitis (ten), and erosions score (ES). *P value of significance of given β. **P value of significance of difference between incident and prevalent RA. P-values
higlighted in italics are significant at p < 0.05
Table 5 Time-lag model: multivariate analyses
Analysis number Predictor β (95% CI) P value Percent variability explained by the model (R2)
1 Previous HAQ 0.762 (0.698; 0.827) <0.001 64.8
Previous PDsynSS -0.017 (-0.027; -0.007) 0.001
2 Previous PDsynSS -0.025 (-0.039; -0.011) <0.001 32.8
Previous DAS28 0.156 (0.109; 0.203) <0.001
3 Previous HAQ 0.703 (0.620; 0.786) <0.001 65.4
Previous PDsynSS -0.022 (-0.034; -0.011) <0.001
Previous DAS28 0.050 (0.005; 0.096) 0.029
4 Previous HAQ 0.754 (0.690; 0.819) <0.001 64.2
Previous GSsynSS -0.009 (-0.017; -0.001) 0.024
5 Previous GSsynSS -0.012 (-0.023; -0.001) 0.036 32.5
Previous DAS28 0.135 (0.088; 0.183) <0.001
6 Previous HAQ 0.707 (0.623; 0.792) <0.001 64.5
Previous GSsynSS -0.013 (-0.022; -0.004) 0.006
Previous DAS28 0.039 (-0.007; 0.085) 0.096
Predicted variable is current health assessment questionnaire (HAQ) score. Predictors used in the six analyses are either previous HAQ score or disease activity
score in 28 joints (DAS28) or both, and previous power Doppler (PD) synovitis (SS) or greyscale (GS) syn sum-score (SS) (previous =measured 12 months ago.
ES = erosions score. P-values higlighted in italics are significant at p < 0.05
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Discussion
Preservation of physical function represents a funda-
mental long‐term outcome for patients with RA. To our
knowledge, this is the first study that systematically ex-
amines the longitudinal relationship between an US joint
inflammation score and physical function in patients
with RA. Several previous studies have informed us on
the relationship between the conventional clinical, radio-
logical and laboratory measures of disease activity and
HAQ evolution [1–4], but we have lacked deeper know-
ledge on the impact of synovitis detected by US on the
HAQ score.
Musculoskeletal US is increasingly being used to
detect and monitor joint inflammation in RA, in both
clinical practice and clinical research. Indeed, both
GSUS and PDUS have been shown to have greater sensi-
tivity for detecting synovitis as compared with physical
examination [9, 10], are more reliable [14–16] and detect
response to therapy more rapidly in comparison to vari-
ous clinical scores [31–34]. Because US examination of
all joints and tendons that can be affected in RA would
be extremely time consuming, several reduced joint
scores for assessing US joint inflammation have been de-
veloped. Concentration on a small number of active
joint regions reduces examination time, but still retains
most of the quantitative information compared to the
extended joint scores [35–39]. It is important to stress
that we have mainly been examining the relationship
between the HAQ score (as a dependent variable), and
the DAS28 and US7S synovitis sum-scores (as explana-
tory variables). This does not mean that we have been
comparing only the additive role of ultrasound examin-
ation to clinical joint counts. DAS28-CRP is a construct
based on a 28-joint count of swollen and tender joints,
patient global assessment and CRP. While most patient-
reported outcome measures tend to be highly correlated,
the representation of the patient global assessment and
the number of tender joints in the DAS28 helps to ex-
plain a substantial part of the variability in HAQ score.
US7S synovitis sum-scores reflect synovitis in the five
joints of the clinically dominant hand (wrist, MCP II, III,
PIPI II, III) and two joints of the foot (MTP II and V),
but synovitis of the wrist is assessed from the dorsal,
volar and ulnar aspects, synovitis of the MCP and PIP
joints from the dorsal and volar aspects, MTP V from
the dorsal and lateral aspects, and MTP II only from the
dorsal aspects. Hence, the joints of the hand (11 joint
areas) are represented much more than the joints of the
foot (3 joint areas) in the sum-scores for PD and GS
synovitis.
Using LLM analysis, we applied two main models - a
standard (current) model and a time-lag model - in a co-
hort of patients with RA that included both patients
with early and with established RA. While the standard
model reflects mainly the cross-sectional relationship
between covariates and predicted variables collected at
the same time, the time-lag model allows for more longi-
tudinal interpretation of the data. When applying the
standard model, the PD and GS synovitis sum-scores
were significantly positively correlated with current
HAQ score and the relative impact of US-detected syno-
vitis was twice as high in patients with early RA as
Table 6 Time-lag model: multivariate analysis, extended model
Predictor Model without US-7 Model with US-7
β (95% CI) P value β (95% CI) P value
Female 0.182 (-0.007; 0.370) 0.059 0.167 (-0.012; 0.347) 0.068
Age (years) 0.172 (0.113; 0.231) <0.001 0.169 (0.113; 0.226) <0.001
BMI 0.009 (-0.009; 0.026) 0.316 0.007 (-0.010; 0.024) 0.405
RF+ or ACPA+ 0.060 (-0.103; 0.224) 0.471 0.052 (-0.106; 0.210) 0.517
Prevalent vs. incident RA 0.026 (-0.156; 0.209) 0.779 0.010 (-0.165; 0.186) 0.910
Previous DAS28-CRP 0.100 (0.061; 0.140) <0.001 0.161 (0.113; 0.208) <0.001
Previous GSsynSS -0.004 (-0.019; 0.010) 0.563
Previous PDsynSS -0.021 (-0.040; -0.002) 0.035
Previous GStenSS 0.000 (-0.085; 0.085) 0.997
Previous PDtenSS -0.015 (-0.078; 0.048) 0.643
Previous erosions score 0.012 (-0.022; 0.046) 0.484
R2 (% variability explained) 32.3 39.1
Improved R2 6.8 <0.001*
Predicted variable is current health assessment questionnaire (HAQ) score. Comparison of models based on baseline demographic, anthropometric and
immunological parameters, and previous disease activity score in 28 joints (DAS28) with or without previous German 7-joint ultrasound score (US7) sum-scores
(SS) (previous =measured 12 months ago). *P value of significance for improvement of prediction. RA rheumatoid arthritis, BMI body mass index, RF rheumatoid factor,
ACPA anti-citrullinated peptide antibodies, GS greyscale, PD power Doppler, syn synovitis, ten tenosynovitis. P-values higlighted in italics are significant at p < 0.05
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compared to those with established disease. A similar
trend was seen in the tenosynovitis score, while the ero-
sions score was not significantly associated with current
HAQ score. This finding is in accordance with other
studies showing that the reversible part of the HAQ
related to disease activity is higher in early RA, while
prolonged duration of the disease increases the part of
the HAQ related to irreversible damage caused by struc-
tural joint damage [1–4, 40–42].
The magnitude of the effect of the individual US7
sum-scores on HAQ score in univariate analyses was
relatively minor (explained percent variability in the
HAQ score was in the range of 3 − 5%) and became sta-
tistically insignificant when adjustments were made for
the conventional clinical and anthropometric variables,
although the performance of the whole multivariate
model was still slightly better when all US7S sum-scores
were entered into the model. These findings suggest that
at least in this population of patients with RA, the ultra-
sound measures included in the US7S were only weakly
associated with overall physical functioning as reflected
by the HAQ score. This may be partly related to the de-
sign of the HAQ itself - although this instrument is cap-
able of detecting small but meaningful changes in
function in individual patients [43], it is dominated by
effects on large joints such as the hips, knees and shoul-
ders (which are not represented in the US7S), and is
relatively insensitive in detecting changes in, for ex-
ample, hand function, which is mainly represented in
the US7S [44, 45].
The results of the time-lag model revealed a somewhat
different perspective. Although the univariate analyses
relating previous US7 sum-scores to current HAQ score
using the time-lag model were non-significant, both
PDsynSS and GSsynSS appeared to be significant predic-
tors of current HAQ after adjustment for the previous
DAS28 or HAQ score, and previous PDsynSS contrib-
uted additional information on current HAQ even in the
more extensive multivariate model. This apparent dis-
cordance may be explained by the fact that by adding
previous HAQ (or DAS28, which is highly correlated
with HAQ) into the multivariate model creates an auto-
regressive model that mainly predicts the change in
HAQ score.
Somewhat counterintuitively, higher PDUS and
GSUS synovitis scores were longitudinally (when
using the time-lag model after adjustment for previ-
ous DAS28 or HAQ) associated with improvement
(not deterioration) of HAQ. This probably reflects the
ability of PDUS and GSUS to discriminate between
the activity-driven reversible part of the HAQ and the
irreversible part of the HAQ caused by structural
damage. The additional analysis on the role of clinical
and US-based measures to determine escalation of
therapy suggested that the main driver of change was
mainly the clinical score, and not the US7S. Although
the treating physicians were allowed to see the results
of the US assessment, they were not actively encour-
aged to apply them in their decision-making, because
the role of the US-based inflammatory score for
treat-to-target strategies was not established. This
may mean that the part of the HAQ associated with
the impact of synovitis detected by PDUS or GSUS is
reversible (either because of change in therapy, or be-
cause of spontaneous fluctuation in disease activity),
and does not necessarily contribute - at least in the
time-frame of one year - to the irreversible part of
the HAQ caused by ensuing structural damage.
Because patients with longer follow up contributed
more data, we compared baseline characteristics be-
tween groups of patients who completed one, two or
three annual follow-up visits and found no significant
trends or differences (Additional file 6).
Our study has several limitations. In our analyses we
treated the US7 sum-scores as a linear continuum,
equalizing the effect of three joints with a PD or GS
signal of 1 to a single joint with a PD or GS signal of 3.
This assumption may not be entirely correct, as shown
by others [46]. However the primary goal of this analysis
was to assess the relationship of one specific US score
(US7S) either alone or in combination with conventional
clinical tools, and hence we used the US7 sum-scores as
designed by its authors. The fact that US examination of
patients was performed by different observers may also be
a limitation of this study, as US is still considered to be
operator-dependent. In order to verify interobserver and
intraobserver agreement among arthro-sonographers in
this project, we performed a reliability study, which was
published elsewhere [28], and showed moderate to excel-
lent results.
Our study also has several strengths. To our know-
ledge, a true longitudinal analysis of the relationship
between an ultrasound inflammation score and physical
function, after adjustment for clinical measures of dis-
ease activity, has never been published. The most im-
portant advantage of longitudinal data analysis,
including the LLM method, is that all available data are
used, which increases the power to detect subtle rela-
tionships. We have analyzed data from 185 patients
overall (46 with incident and 139 with prevalent disease)
and 522 follow-up visits.
Conclusions
In conclusion, we found that US7 PD and GS synovitis
sum-scores alone were positively associated with current
functional status reflected by the HAQ score in RA
patients, and this relationship was stronger in patients
with early disease. However, they contributed little
Závada et al. Arthritis Research & Therapy  (2017) 19:5 Page 8 of 10
additional information on the current HAQ score, be-
yond standard clinical measures. When combined with
the DAS28, or HAQ, US7 PD and GS synovitis sum-
scores were predictive of the change in HAQ score over
one year. Based on the multivariate analyses of the time-
lag model and taking into the account the results of
univariate analyses of the standard model we may
assume that US7S sum-scores for synovitis were associ-
ated mainly with the reversible activity-related compo-
nent of HAQ, and may thus help to identify patients
with higher chance of functional improvement. Although
the interpretation of the results is not straightforward,
our study adds further argument to caution against
indiscriminate use of more aggressive therapeutic
approaches (with the aim of preventing irreversible dam-
age) based on information from the US inflammatory
score, beyond standard clinical activity indexes.
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